[go: up one dir, main page]

PE20090153A1 - Metodo para producir una proteina en un cultivo de celulas en base a ph y temperatura reducida - Google Patents

Metodo para producir una proteina en un cultivo de celulas en base a ph y temperatura reducida

Info

Publication number
PE20090153A1
PE20090153A1 PE2008000691A PE2008000691A PE20090153A1 PE 20090153 A1 PE20090153 A1 PE 20090153A1 PE 2008000691 A PE2008000691 A PE 2008000691A PE 2008000691 A PE2008000691 A PE 2008000691A PE 20090153 A1 PE20090153 A1 PE 20090153A1
Authority
PE
Peru
Prior art keywords
cell culture
protein
reduced temperature
produce
culture based
Prior art date
Application number
PE2008000691A
Other languages
English (en)
Inventor
Jose Manuel Gomes
Gregory Walter Hiller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39493848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20090153A1 publication Critical patent/PE20090153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO PARA PRODUCIR UNA PROTEINA A PARTIR DE UN CULTIVO DE CELULAS, LAS CUALES SON PROCEDENTE DE MAMIFEROS PREFERENTEMENTE CELULAS DE OVARIO DE HAMSTER CHINO. DICHO METODO COMPRENDE POR LO MENOS UNA DE LAS SIGUIENTES CONDICIONES: a)CULTIVO CELULAR A TEMPERATURA REDUCIDA, TA COMO 27‘C A 30‘C; Y b)CULTIVO CELULAR A pH REDUCIDO, TAL COMO 6.8 A 7; DONDE EL OBJETIVO ES REDUCIR LA PRODUCCION DE PROTEINAS MAL PLEGADAS Y/O PROTEINAS AGREGADAS EN BASE A MODIFICACIONES EN EL NIVEL DE GLICOSILACION. TAMBIEN SE REFIERE A ETAPAS DE AISLAMIENTO, PURIFICACION Y PROCESADO EN UNA COMPOSICION FARMACEUTICA
PE2008000691A 2007-04-23 2008-04-22 Metodo para producir una proteina en un cultivo de celulas en base a ph y temperatura reducida PE20090153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91338207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
PE20090153A1 true PE20090153A1 (es) 2009-04-23

Family

ID=39493848

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000686A PE20090731A1 (es) 2007-04-23 2008-04-21 Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia
PE2008000691A PE20090153A1 (es) 2007-04-23 2008-04-22 Metodo para producir una proteina en un cultivo de celulas en base a ph y temperatura reducida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008000686A PE20090731A1 (es) 2007-04-23 2008-04-21 Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia

Country Status (26)

Country Link
US (2) US12054762B2 (es)
EP (2) EP2139987B9 (es)
JP (3) JP5557736B2 (es)
KR (3) KR101560421B1 (es)
CN (3) CN101679943A (es)
AR (2) AR066238A1 (es)
AU (2) AU2008242632B2 (es)
BR (2) BRPI0810511A2 (es)
CA (2) CA2685552C (es)
CL (2) CL2008001159A1 (es)
CO (2) CO6241165A2 (es)
DK (2) DK2139987T5 (es)
ES (2) ES2646090T3 (es)
HK (1) HK1216261A1 (es)
HU (1) HUE034776T2 (es)
IL (2) IL201720A (es)
MX (2) MX2009011363A (es)
PA (2) PA8777701A1 (es)
PE (2) PE20090731A1 (es)
PL (2) PL2139987T3 (es)
PT (2) PT2139986T (es)
RU (2) RU2478702C2 (es)
SI (2) SI2139987T1 (es)
TW (2) TW200902708A (es)
WO (2) WO2008131375A1 (es)
ZA (1) ZA200907426B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
WO2009023562A2 (en) * 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
EP3862423A1 (en) 2010-04-26 2021-08-11 Novartis AG Improved cell cultivation process
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
KR20210037745A (ko) 2013-03-15 2021-04-06 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
SG11201507875RA (en) * 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
TW201446961A (zh) 2013-05-06 2014-12-16 Abbvie Inc 用於細胞培養之組合物及其使用方法
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
USD759075S1 (en) * 2014-04-11 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
USD759076S1 (en) * 2014-04-18 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
EP3207132B1 (en) * 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
EP3529350A1 (en) 2016-10-19 2019-08-28 H. Hoffnabb-La Roche Ag Method for producing an immunoconjugate
JP7252896B2 (ja) * 2017-02-17 2023-04-05 ロンザ リミテッド 生物学的産物バリアントを産生する方法
US20190112569A1 (en) * 2017-10-16 2019-04-18 Regeneron Pharmaceuticals, Inc. In Situ Raman Spectroscopy Systems and Methods for Controlling Process Variables in Cell Cultures
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
JP7707062B2 (ja) * 2018-11-02 2025-07-14 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
JP7570341B2 (ja) * 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
BR112022013255A2 (pt) 2020-01-09 2022-09-06 Mersana Therapeutics Inc Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
JP2022184798A (ja) * 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
EP4640838A1 (en) * 2022-12-23 2025-10-29 Cell Exosome Therapeutics Inc. Utilization of mesenchymal stem cells or culture supernatant thereof
CN120752329A (zh) * 2023-02-03 2025-10-03 安进公司 细胞培养方法
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
CN118006716B (zh) * 2024-03-15 2024-09-10 通化安睿特生物制药股份有限公司 制备高表达且低o-糖基化水平的重组人白蛋白的方法
TWI891362B (zh) * 2024-05-10 2025-07-21 國立臺灣大學 鴨蛋白水解物及其製備方法及增強肌肉耐力與抗疲勞用途
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5610033A (en) 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
WO1992009298A1 (en) * 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
JP4215172B2 (ja) * 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1999035255A2 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
DE60042114D1 (de) 1999-04-30 2009-06-10 Craig J Venter Inst Inc Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
JP3090657B1 (ja) 1999-08-09 2000-09-25 伸子 蓮山 ゼオライト製造方法およびゼオライト製造装置
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
AUPR038200A0 (en) * 2000-09-26 2000-10-19 Beta Peptide Foundation Pty Ltd, The Compositions and methods for delaying, preventing, rejuvenating or reversing senescence
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6544076B2 (en) 2001-07-10 2003-04-08 Alan L. Pocrass Dual function RJ connector
EP1448786B1 (en) * 2001-11-19 2010-04-14 Novo Nordisk A/S Process for preparing insulin compounds
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US6872549B2 (en) * 2002-03-27 2005-03-29 Immunex Corporation Methods for increasing polypeptide production
GB0208041D0 (en) 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
EP1520008B1 (en) 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
PL376381A1 (en) 2002-07-15 2005-12-27 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP1620457A2 (en) 2003-04-25 2006-02-01 Immunex Corporation Inducers of recombinant protein expression
CN1565631A (zh) * 2003-06-27 2005-01-19 上海中信国健药业有限公司 肿瘤坏死因子受体－免疫球蛋白的融合蛋白用于急性肺损伤药物的用途
PL1678208T3 (pl) 2003-10-27 2013-09-30 Wyeth Llc Usuwanie agregatów o wysokiej masie cząsteczkowej z użyciem chromatografii na hydroksyapatycie
WO2005064013A1 (en) 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
ATE464918T1 (de) * 2004-07-07 2010-05-15 Coloplast As Herstellung von hydrophilen überzügen mit einer 1,3-dioxolan-verbindung
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
EP1781684A4 (en) 2004-08-25 2008-05-21 Amprotein Corp NEW CHIMERE POLYPEPTIDE AND USE THEREOF
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents
US20070102622A1 (en) 2005-07-01 2007-05-10 Olsen Richard I Apparatus for multiple camera devices and method of operating same
WO2007011595A2 (en) 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
DE102005034616B4 (de) * 2005-07-18 2008-07-03 Elringklinger Ag Brennstoffzelleneinheit und Brennstoffzellenstapel
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
RU2463345C2 (ru) * 2006-07-13 2012-10-10 Вайет Получение гликопротеинов
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
JP7587678B2 (ja) 2021-09-15 2024-11-20 香港時代新能源科技有限公司 電池セル、電池、電力消費装置、電池セルの製造方法及び設備

Also Published As

Publication number Publication date
DK2139986T3 (en) 2017-10-02
PL2139987T3 (pl) 2013-11-29
WO2008131375A1 (en) 2008-10-30
SI2139987T1 (sl) 2013-09-30
KR101560421B1 (ko) 2015-10-15
AR066238A1 (es) 2009-08-05
PE20090731A1 (es) 2009-07-15
CN105039473A (zh) 2015-11-11
US20080269132A1 (en) 2008-10-30
EP2139986A1 (en) 2010-01-06
CO6241166A2 (es) 2011-01-20
ES2424217T9 (es) 2014-01-27
EP2139987B9 (en) 2013-11-13
AU2008242632B2 (en) 2013-11-28
RU2009138226A (ru) 2011-05-27
CL2008001156A1 (es) 2009-01-16
CA2684727A1 (en) 2008-10-30
RU2009139054A (ru) 2011-05-27
US9988662B2 (en) 2018-06-05
DK2139987T5 (da) 2014-01-27
BRPI0810511A2 (pt) 2014-10-07
TW200902709A (en) 2009-01-16
EP2139986B1 (en) 2017-09-06
PA8777701A1 (es) 2008-11-19
ES2424217T3 (es) 2013-09-30
US20080274507A1 (en) 2008-11-06
ZA200907426B (en) 2010-08-25
AU2008242633A1 (en) 2008-10-30
CN101679943A (zh) 2010-03-24
AU2008242633B2 (en) 2014-09-18
MX2009011363A (es) 2009-11-05
HK1216261A1 (zh) 2016-10-28
PT2139986T (pt) 2017-11-14
CN101668845B (zh) 2015-11-25
JP2010524503A (ja) 2010-07-22
JP2010524504A (ja) 2010-07-22
DK2139987T3 (da) 2013-09-02
IL201720A (en) 2016-03-31
HUE034776T2 (en) 2018-02-28
IL201719A0 (en) 2011-08-01
KR20140132016A (ko) 2014-11-14
CN101668845A (zh) 2010-03-10
CA2685552C (en) 2016-02-23
MX2009011362A (es) 2009-11-05
CO6241165A2 (es) 2011-01-20
IL201719A (en) 2015-09-24
PL2139986T3 (pl) 2018-01-31
WO2008131374A1 (en) 2008-10-30
ES2646090T3 (es) 2017-12-12
PA8778001A1 (es) 2008-11-19
TW200902708A (en) 2009-01-16
EP2139987A1 (en) 2010-01-06
BRPI0810482A2 (pt) 2014-10-07
RU2478702C2 (ru) 2013-04-10
IL201720A0 (en) 2011-08-01
JP2014113161A (ja) 2014-06-26
CL2008001159A1 (es) 2008-11-03
SI2139986T1 (sl) 2017-11-30
AU2008242632A1 (en) 2008-10-30
JP5881755B2 (ja) 2016-03-09
PT2139987E (pt) 2013-08-22
KR101540124B1 (ko) 2015-07-28
AR066239A1 (es) 2009-08-05
CA2684727C (en) 2018-09-04
KR20100017211A (ko) 2010-02-16
JP5557736B2 (ja) 2014-07-23
KR20100016271A (ko) 2010-02-12
HK1142095A1 (zh) 2010-11-26
EP2139987B1 (en) 2013-07-03
US12054762B2 (en) 2024-08-06
CA2685552A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
PE20090153A1 (es) Metodo para producir una proteina en un cultivo de celulas en base a ph y temperatura reducida
MX2009002388A (es) Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
CY1108571T1 (el) Διεργασια για την παραγωγη και τον καθαρισμο ερυθροποιητινης
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
DE112007001307A5 (de) Mikrobiologische Herstellung von 3-Hydroxyisobuttersäure
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
BRPI0810003A2 (pt) "produção de proteínas de alta manose em cultura de plantas"
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
BRPI0519285A2 (pt) biomaterial implatável e método de produzir o mesmo
EA201200516A1 (ru) Способ продуцирования молекул, содержащих специализированные гликановые структуры
BR112013026559A2 (pt) "cepas variantes de fundos filamentosos tendo modificação genética para maior produção de proteína gas1 e crescimento alterado e seu método de produção".
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
UY29149A1 (es) Tiazolil-dihidro-indazoles
FR2894869B1 (fr) Procede de fabrication d'un fuselage d'aeronef en materiau composite
BRPI0413180A (pt) gorduras de baixo teor de ácido trans-groxo e composições de gorduras, e métodos de fazer as mesmas
WO2006133356A3 (en) Elimination of n-glycolylneuraminic acid from mammalian products for human use
PT1969127E (pt) Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
CL2008002118A1 (es) Metodo para la produccion de un embrion equino de sexo seleccionado mediante la inyeccion intracitoplasmatica de esperma utilizando espermatozoides de equino seleccionados por sexo.
AR054252A1 (es) Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina
PE20141826A1 (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones
EP2076589A4 (en) METHOD FOR PRODUCING NATIVE COMPONENTS, SUCH AS GROWTH FACTORS OR EXTRACELLULAR MATRIX PROTEINS, BY CELL CULTIVATION OF TISSUE SAMPLES FOR TISSUE REPAIR
BR112012008791A2 (pt) Produção de resíduos comestíveis a partir da produção de etanol.

Legal Events

Date Code Title Description
FX Voluntary withdrawal